Litigation Details for Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Docket		Date Filed	2016-12-12
Court	District Court, D. Delaware	Date Terminated	2016-12-28
Cause	35:0145	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	6,124,363
Link to Docket	External link to docket

Details for Apicore US LLC v. Pfizer Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-12				External link to document
2016-12-11	1		United States Patent No. 6,124,363 (the “’363 Patent”) to enable Apicore to achieve patent certainty as… THE ’363 PATENT 26. The ’363 patent is entitled “DOFETILIDE POLYMORPHS…and interest in the ’363 patent. A true and correct copy of the ’363 patent is attached hereto as Exhibit…-infringement of the ’363 patent. This actual controversy regarding patent certainty is defined by 21…This is a declaratory judgment action is under the patent laws of the United States, 35 U.S.C. § 1 et seq	External link to document
2016-12-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,124,363. (ceg) (Entered: 12… 28 December 2016 1:16-cv-01174 830 Patent None District Court, D. Delaware	External link to document
2016-12-11	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,124,363. (Attachments: # 1 … 28 December 2016 1:16-cv-01174 830 Patent None District Court, D. Delaware	External link to document

Apicore US LLC v. Pfizer Inc. Litigation Summary and Patent Analysis, 1:16-cv-01174

Last updated: August 25, 2026

Apicore US LLC v. Pfizer Inc., No. 1:16-cv-01174, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Apicore’s abbreviated new drug application for a generic version of Xeljanz, Pfizer’s tofacitinib product. The case concerned Pfizer’s listed patent rights covering tofacitinib and its pharmaceutical use. The public docket reflects a resolution and dismissal rather than a merits judgment invalidating Pfizer’s patent estate.[1]

What drug and regulatory pathway were involved in Apicore v. Pfizer?

The dispute involved tofacitinib, the active pharmaceutical ingredient in Xeljanz. Xeljanz is an oral Janus kinase inhibitor approved by the FDA for specified inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.[2]

Apicore proceeded through the ANDA pathway under the Hatch-Waxman Act. An ANDA applicant must address patents listed by the reference-product sponsor in the FDA Orange Book. The relevant certification is generally one of the following:

Certification	Effect
Paragraph I	No patent is listed
Paragraph II	The listed patent has expired
Paragraph III	The applicant will wait until patent expiration
Paragraph IV	The patent is invalid, unenforceable, or will not be infringed

Apicore’s litigation position was based on a Paragraph IV challenge. The filing of a Paragraph IV certification can constitute an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the patent holder to sue before commercial launch.[3]

What patents protected Xeljanz and tofacitinib?

The principal patent associated with the early tofacitinib litigation was U.S. Patent No. 6,956,041, commonly identified as the basic composition-of-matter patent for tofacitinib-related compounds. Pfizer and its related entities also asserted or maintained later patent rights directed to formulations, crystalline forms, pharmaceutical compositions, and methods of treatment.

Core patent categories

Patent category	Subject matter	Commercial relevance
Composition of matter	Tofacitinib and related imidazopyrazine compounds	Primary barrier to generic launch
Solid-state or crystalline form	Tofacitinib citrate forms and related physical properties	Can extend protection after the compound patent
Pharmaceutical composition	Dosage forms and excipient combinations	Supports formulation-specific enforcement
Method of treatment	Use of tofacitinib for autoimmune or inflammatory disease	Can restrict labeling-based generic launch
Dosage regimen	Dose, administration schedule, or patient population	May create additional infringement risk

The Orange Book status must be assessed patent-by-patent and product-by-product. Listed patents can change over time through patent expiration, delisting, corrections, and FDA updates. The FDA Orange Book, rather than a secondary litigation summary, is the controlling source for the current listed-patent position.[4]

When did Pfizer’s main tofacitinib patent protection expire?

U.S. Patent No. 6,956,041 had an adjusted expiration date extending beyond the ordinary 20-year patent term because of patent-term adjustment. Public patent records associate the patent with an expiration date in 2025. Later-listed patents and regulatory exclusivities created additional barriers to immediate generic launch.[5]

The relevant exclusivity analysis is:

Protection	Approximate commercial effect
New chemical entity exclusivity	Delayed ANDA approval during the statutory exclusivity period
Basic compound patent	Protected the active ingredient and core chemical claims
Later formulation and method patents	Potentially extended enforcement risk after core patent expiry
Pediatric exclusivity, if applicable	Can add six months to qualifying exclusivity or patent protection
Settlement restrictions	Can determine the earliest agreed generic entry date

Patent expiry alone does not establish immediate market entry. The applicant must also obtain FDA approval, resolve all remaining listed-patent issues, and comply with any settlement or regulatory restrictions.

What was the litigation timeline in 1:16-cv-01174?

The case was filed in 2016 in the District of Delaware. It followed Apicore’s ANDA activity and its Paragraph IV position concerning Pfizer’s Xeljanz-related patents.

Timeline

Date	Event
2016	Apicore filed the Delaware patent action against Pfizer
2016-2017	The parties litigated the ANDA-related patent claims and defenses
2017	The docket reflected resolution of the dispute and dismissal
After dismissal	No public merits judgment established invalidity of Pfizer’s principal patent rights in this action

The case did not produce a reported trial verdict that invalidated the asserted Pfizer patents. Its commercial importance therefore rests primarily on the settlement and the resulting generic-entry framework, not on a judicial determination that Pfizer’s patent estate was unenforceable.

Was the case a Paragraph IV challenge?

Yes. The case fits the standard Paragraph IV framework for a generic applicant challenging Orange Book-listed patents.

A Paragraph IV case typically raises:

• Patent invalidity, including anticipation, obviousness, lack of written description, or lack of enablement.
• Noninfringement of the asserted claims.
• Unenforceability based on inequitable conduct or other misconduct.
• Whether the ANDA product’s proposed label induces infringement of method-of-use claims.
• Whether the applicant can launch before the patent expiration date under a settlement.

The Paragraph IV notice letter is usually the event that triggers the 45-day period during which the brand company may file suit. A timely suit can impose a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court orders.[3]

What was the litigation outcome?

The publicly available docket indicates that the dispute ended through settlement-related dismissal. The action did not result in a published decision holding Pfizer’s core tofacitinib patents invalid or unenforceable.

The dismissal has several practical implications:

1. Apicore did not obtain a litigation-based right to launch immediately.
2. Pfizer retained the benefit of its patent positions until expiration or settlement-authorized entry.
3. The parties’ private settlement terms controlled the commercial launch date and other restrictions.
4. The absence of a merits decision limited the precedential value of the case.
5. Other generic applicants remained free to bring separate challenges, subject to claim preclusion, settlement terms, and the status of the listed patents.

Settlement dismissals in Hatch-Waxman cases often contain confidential entry dates, manufacturing restrictions, licensing provisions, covenants not to sue, or acceleration provisions. Unless the agreement is publicly filed or disclosed through a regulatory filing, the exact terms cannot be inferred from the dismissal alone.

Did the case establish a precedent on tofacitinib patent validity?

No. The case did not establish a reported precedent invalidating Pfizer’s tofacitinib patent estate.

That distinction matters for later generic challengers. A settlement dismissal:

• Does not constitute a finding that the patent is valid.
• Does not constitute a finding that the patent is invalid.
• Does not bind unrelated ANDA applicants in the same way as a final judgment after litigation.
• Does not remove Orange Book-listed patents unless the sponsor or FDA takes the required administrative action.
• Does not by itself determine whether a later applicant can rely on the same invalidity or noninfringement arguments.

The strongest legal evidence of patent weakness would have been a final judgment, an adverse claim-construction ruling, an inter partes review decision, or a Federal Circuit opinion. The Apicore docket does not provide that type of merits outcome.

What was the Orange Book status of Xeljanz?

Xeljanz was approved as an NDA product, and Pfizer listed patents associated with the product in the Orange Book. The precise listed-patent status depends on the product and dosage form, including immediate-release tablets, extended-release tablets, and oral solution presentations.

Orange Book issues relevant to generic entry

A generic applicant must evaluate:

• Whether the ANDA product matches the reference-listed drug dosage form.
• Whether the proposed label overlaps patented methods of treatment.
• Whether the listed patents cover the active ingredient, formulation, or use.
• Whether skinny-label provisions can omit patented indications.
• Whether the FDA has accepted the applicant’s certification.
• Whether a 30-month stay remains in effect.
• Whether pediatric or other regulatory exclusivity blocks approval.

Method-of-use patents are particularly important for Xeljanz because different indications and dosing regimens have been approved over time. A generic applicant may attempt to omit patented indications from its label, but the success of that strategy depends on the scope of the remaining label and the infringement theory advanced by the patent holder.

Were formulation patents important in the Apicore dispute?

Formulation and solid-state patents can materially affect generic risk even after expiration of the basic compound patent.

A formulation patent may cover:

• A tablet composition.
• A specific salt or crystalline form.
• Particle-size parameters.
• Stability characteristics.
• Release profiles.
• Extended-release delivery.
• Manufacturing conditions that produce a claimed solid form.

For a generic applicant, the practical question is not whether a formulation patent exists in isolation. The question is whether the ANDA product necessarily practices the asserted claims. A product can avoid infringement by using a different salt, polymorph, excipient system, manufacturing process, or release mechanism, provided the alternative complies with FDA requirements.

What manufacturing and intellectual-property barriers applied?

Tofacitinib generic entry required more than chemical synthesis of the active ingredient. A commercial applicant had to address:

• API manufacturing controls.
• Salt and polymorph control.
• Impurity specifications.
• Bioequivalence for the selected dosage form.
• Stability and dissolution requirements.
• Process patents and manufacturing know-how.
• Patent claims directed to the final dosage form.
• Method-of-use claims retained in the approved label.

Manufacturing patents can be harder to identify than Orange Book patents because process patents are not always listed for an approved drug. They may still create litigation exposure if the brand company obtains evidence regarding the generic applicant’s API source, process, or product composition.

How strong was Pfizer’s patent estate against Apicore?

Pfizer’s estate was commercially meaningful because it combined the basic compound patent with later-issued patents and regulatory exclusivity. The estate’s strength varied by patent type.

Estate component	Relative strength against a generic
Core compound claims	Strongest if valid and directly covering tofacitinib
Formulation claims	Dependent on the exact ANDA composition
Solid-state claims	Dependent on salt, polymorph, and characterization data
Method-of-use claims	Vulnerable to label design and indication carve-outs
Process claims	Dependent on manufacturing evidence and discovery
Later-issued patents	Can delay launch but face validity and infringement challenges

The settlement outcome prevented the court from testing these issues in a final decision. The case therefore indicates meaningful commercial leverage for Pfizer, but it does not independently prove that every asserted patent would have survived trial.

Which companies challenged Xeljanz patent protection?

The Xeljanz patent landscape included multiple generic applicants and related ANDA litigation. The competitive field included companies pursuing generic tofacitinib through Paragraph IV certifications and companies evaluating launch timing after core patent expiry.

The main competitive variables were:

• Whether an applicant challenged the compound patent or only later patents.
• Whether the applicant sought approval for immediate-release or extended-release products.
• Whether the applicant used a skinny label.
• Whether the applicant settled with Pfizer.
• Whether the applicant obtained first-filer status.
• Whether the applicant’s settlement permitted an early authorized or licensed launch.

A single settlement with Apicore did not establish the entry date for every other generic applicant. Each applicant’s certification, settlement, and approval status had to be analyzed separately.

What generic launch risks existed after settlement?

The principal launch scenarios were:

Settlement-authorized entry

Apicore could enter on the date and terms negotiated with Pfizer, subject to FDA approval and compliance with the agreement.

Launch after patent expiry

If no enforceable patent or regulatory exclusivity remained, Apicore could launch after approval and expiration of the relevant protection.

At-risk launch

An applicant could launch before final resolution of patent disputes, exposing itself to damages, an injunction, or a later finding of infringement. A settlement generally reduces that risk by establishing contractual entry terms.

Delayed approval

FDA approval could remain blocked by a 30-month stay, regulatory exclusivity, unresolved certification issues, or deficiencies in the ANDA.

Did biosimilar risk apply to Xeljanz?

No. Xeljanz is a small-molecule drug, not a biologic. The relevant pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The competitive threat was generic substitution rather than biosimilar interchangeability. Patent analysis therefore focused on Paragraph IV certifications, Orange Book listings, ANDA labeling, bioequivalence, and small-molecule patent litigation.

What was Pfizer’s revenue exposure?

Xeljanz was a major Pfizer commercial product, and generic entry created potential erosion across multiple indications and dosage forms. Revenue exposure depended on:

• The earliest permitted generic-entry date.
• Whether entry was single-source or multisource.
• The availability of extended-release and oral-solution generics.
• Rebate and contracting behavior.
• Physician switching and formulary placement.
• Whether Pfizer shifted patients to other immunology products.
• The scope of any authorized-generic or license arrangement.

A settlement could preserve substantial branded revenue before the agreed entry date while reducing the risk of an earlier at-risk launch. Exact settlement economics were not established by the public dismissal alone.

Key Takeaways

• Apicore US LLC v. Pfizer Inc., No. 1:16-cv-01174, was a Delaware Hatch-Waxman action involving generic tofacitinib and Pfizer’s Xeljanz patent rights.
• Apicore’s challenge was based on the ANDA Paragraph IV framework.
• U.S. Patent No. 6,956,041 was a central patent in the tofacitinib estate and had patent protection extending into 2025 through patent-term adjustment.
• Later formulation, solid-state, dosage, and method-of-use patents created additional entry risks.
• The case ended through settlement-related dismissal rather than a merits judgment.
• The docket did not establish that Pfizer’s asserted patents were invalid or unenforceable.
• The dispute involved a small-molecule generic, not a biosimilar.
• Commercial entry depended on the settlement terms, FDA approval, Orange Book status, and any remaining patent or regulatory exclusivity.

Frequently Asked Questions

What was Apicore’s generic product in the Pfizer lawsuit?

Apicore’s product was a proposed generic version of Xeljanz containing tofacitinib.

Was Apicore allowed to launch immediately after the case was dismissed?

No. Dismissal did not itself authorize commercial launch. FDA approval and the settlement’s entry provisions remained controlling.

Did Apicore win invalidation of Pfizer’s Xeljanz patents?

No. The case ended without a reported merits judgment invalidating Pfizer’s patents.

Does the Apicore settlement bind later generic applicants?

Generally, no. Other ANDA applicants remain subject to their own certifications, litigation, settlements, and FDA approval requirements.

Can a generic launch with a label excluding patented Xeljanz indications?

Potentially, through a section viii or skinny-label strategy, but the resulting label and product must avoid infringement of the remaining enforceable method-of-use claims.

References

1. U.S. District Court for the District of Delaware. (2016-2017). Apicore US LLC v. Pfizer Inc., No. 1:16-cv-01174. PACER/Court docket records.

2. U.S. Food and Drug Administration. (2022). Xeljanz (tofacitinib) prescribing information. Pfizer Laboratories.

3. 35 U.S.C. §§ 271(e)(2), 355(j).

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,956,041, Imidazopyrazine compounds. Washington, DC.